Stuart A. Arbuckle, Director of Rhythm Pharmaceuticals RYTM, has filed 0 purchases and 30 sales on the open market. The latest trade was on 06/24.

SA

SA

Stuart A. Arbuckle

Director

Company

Rhythm Pharmaceuticals RYTM

First filing

23/02/03

Trades

96 trades

Buys / sales

0 / 30

12-month net buying

No record

Last trade

06/24

FollowShare

Trading activity

6 months1 year2 years5 yearsAll

Transactions

Company	Trade type	Traded	Filed	Shares	Price	Value	Holding change
Vertex PharmaceuticalsVRTX	Open-market sale10b5-1 plan	24/05/15	24/05/17	69 sh	$430.93	$29,734.17	−0.1%
Vertex PharmaceuticalsVRTX	Open-market sale10b5-1 plan	24/02/26	24/02/27	5,034 sh	$425.70	$2,142,973.8	−9.2%
Vertex PharmaceuticalsVRTX	Open-market sale10b5-1 plan	24/02/21	24/02/23	3,603 sh	$421.77	$1,519,637.31	−5.7%
Vertex PharmaceuticalsVRTX	Open-market sale10b5-1 plan	24/02/20	24/02/21	4,804 sh	$420.79	$2,021,475.16	−7.1%
Vertex PharmaceuticalsVRTX	Open-market sale10b5-1 plan	24/02/12	24/02/13	4,295 sh	$420.24	$1,804,930.8	−5.4%
Vertex PharmaceuticalsVRTX	Open-market sale10b5-1 plan	23/12/13	23/12/15	8,603 sh	$399.00	$3,432,597	−13.2%
Vertex PharmaceuticalsVRTX	Open-market sale10b5-1 plan	23/06/15	23/06/20	8,603 sh	$349.00	$3,002,447	−13.2%
Vertex PharmaceuticalsVRTX	Open-market sale10b5-1 plan	23/05/30	23/06/01	82 sh	$329.82	$27,045.24	−0.1%
Vertex PharmaceuticalsVRTX	Open-market sale	23/02/27	23/02/28	5,034 sh3 trades	$287.47avg.	$1,447,143.44	−8.2%
Vertex PharmaceuticalsVRTX	Open-market sale	23/02/22	23/02/24	2,401 sh5 trades	$294.33avg.	$706,678.7	−3.5%
Vertex PharmaceuticalsVRTX	Open-market sale	23/02/21	23/02/22	2,402 sh4 trades	$293.75avg.	$705,595.74	−3.4%
Vertex PharmaceuticalsVRTX	Open-market sale	23/02/14	23/02/16	6,398 sh6 trades	$298.68avg.	$1,910,961.7	−7.8%
Vertex PharmaceuticalsVRTX	Open-market sale	23/02/13	23/02/14	4,887 sh4 trades	$298.92avg.	$1,460,815.65	−5.6%